Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains delta-9-tetrahydrocannabinol (THC)...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Schizophrenia01:17

Schizophrenia

Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Therapeutic Mechanism for Nicotine Craving in Schizophrenia.

medRxiv : the preprint server for health sciences·2026
Same author

Smoking cessation for people with severe mental illness: systematic review and network meta-analysis.

BMJ medicine·2026
Same author

Impulsivity-related predictors of adolescent substance use initiation.

Psychological medicine·2026
Same author

Detection of Δ9-Tetrahydrocannabinol Impairment Using Resting-State Functional Near-Infrared Spectroscopy: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Electrographic cue-reactivity co-localizes with accumbens deep brain stimulation in a case of opioid use disorder.

Nature communications·2026
Same author

Neurocognitive outcomes in adolescents with and without four weeks of cannabis abstinence: a randomized clinical trial using contingency management.

Frontiers in psychiatry·2026
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Does using marijuana increase the risk for developing schizophrenia?

A Eden Evins1, Alan I Green, John M Kane

  • 1Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.

The Journal of Clinical Psychiatry
|May 10, 2013
PubMed
Summary
This summary is machine-generated.

Legalizing marijuana may increase schizophrenia risk in adolescents. Research links cannabis use to psychosis vulnerability, especially in young people.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Area of Science:

  • Neuroscience
  • Psychiatry
  • Public Health

Background:

  • Increasing marijuana legalization globally necessitates understanding its health impacts.
  • Previous research indicates a correlation between adolescent cannabis use and heightened schizophrenia risk.
  • Vulnerable populations, particularly young individuals, face elevated psychosis risks.

Purpose of the Study:

  • To inform clinicians about the potential effects of marijuana use.
  • To review the link between cannabis and schizophrenia in adolescents.
  • To explore factors influencing schizophrenia risk associated with cannabis.

Main Methods:

  • An international expert panel convened to discuss marijuana's effects.
  • Review of existing research on cannabis potency and adolescent use.
  • Analysis of concurrent drug use and its impact on schizophrenia risk.

Main Results:

  • Cannabis use is associated with an increased risk of schizophrenia in vulnerable adolescents.
  • Potency of cannabis and concurrent drug use are significant factors.
  • Expert consensus highlights the need for clinical awareness.

Conclusions:

  • Clinicians must be aware of the association between marijuana use and schizophrenia risk in adolescents.
  • Further research is needed to understand the mechanisms and mitigate risks.
  • Public health strategies should consider the implications of marijuana legalization on mental health.